Savers Value Village, Inc. (SVV)

Revance Therapeutics Stock Forecast

Stock Price Forecast

The 7 analysts that cover Revance Therapeutics stock have a consensus rating of "Buy" and an average price target of $12.57, which forecasts a 9.59% increase in the stock price over the next year. The lowest target is $10 and the highest is $15.

Price Target: $12.57 (+9.59%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$10	$12.57	$13	$15
Change	-12.82%	+9.59%	+13.34%	+30.78%

Analyst Ratings

The average analyst rating for Revance Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	2	2	2	2	2	2
Buy	1	1	2	2	3	3
Hold	3	3	3	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	7	7	8	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Matthew Boss JP Morgan	JP Morgan	Hold Maintains $9 → $11	Hold	Maintains	$9 → $11	-4.10%	Jul 28, 2025
Owen Rickert Northland Capital Markets	Northland Capital Markets	Buy Initiates $15	Buy	Initiates	$15	+30.78%	Jun 10, 2025
Brooke Roach Goldman Sachs	Goldman Sachs	Hold Maintains $9 → $10	Hold	Maintains	$9 → $10	-12.82%	May 2, 2025
Peter Keith Piper Sandler	Piper Sandler	Hold Maintains $10 → $11	Hold	Maintains	$10 → $11	-4.10%	May 2, 2025
Dylan Carden William Blair	William Blair	Buy Initiates n/a	Buy	Initiates	n/a	n/a	Apr 4, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

1.65B

Increased by 7.50%

from 1.54B

Revenue Next Year

1.77B

Increased by 7.26%

from 1.65B

EPS This Year

0.44

Increased by 159.43%

from 0.17

EPS Next Year

0.56

Increased by 27.23%

from 0.44

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Jan 2, 2021	Jan 1, 2022	Dec 31, 2022	Dec 30, 2023	Dec 28, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	834.01M	1.20B	1.44B	1.50B	1.54B	1.65B	1.77B	1.92B
Revenue Growth	-30.82%	44.38%	19.36%	4.39%	2.49%	7.50%	7.26%	8.46%
EPS	-0.34	0.57	0.58	0.34	0.17	0.44	0.56	0.75
EPS Growth	-	-	1.75%	-41.38%	-50.00%	159.43%	27.23%	33.20%
Forward PE	-	-	-	-	-	26.01	20.44	15.35
No. Analysts	-	-	-	-	-	10	10	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	1.7B	1.9B	2.0B
Avg	1.7B	1.8B	1.9B
Low	1.6B	1.7B	1.8B

Revenue Growth

Revenue Growth	2025	2026	2027
High	12.6%	13.6%	14.8%
Avg	7.5%	7.3%	8.5%
Low	3.2%	0.4%	2.9%

EPS Forecast

EPS	2025	2026	2027
High	0.50	0.63	0.80
Avg	0.44	0.56	0.75
Low	0.41	0.45	0.71

EPS Growth

EPS Growth	2025	2026	2027
High	196.5%	42.8%	42.2%
Avg	159.4%	27.2%	33.2%
Low	142.1%	2.2%	25.7%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.